Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

At the parallel event, executives from leading pharma companies like Pfizer and AstraZeneca will talk about the ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of ...

As the company restructures, it will pivot to selling genetic tests to consumers and using that data for research. Also: medicinal and tech advancements in cancer care; research monkeys roundup.

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Dr. Mackay is a highly accomplished R&D executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. SpringWorks uses ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Ruane specifically targeted individuals, such as Sir Chris, and the chief executive officer of Covid vaccine developer Pfizer in a series of posts ... In response to the creator of the AstraZeneca ...